Company: INTS
Filing Date: 2025-06-11
Form Type: 424B5
Source: 0001628280-25-030702
Chunk: 1

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-11
Form: 424B5
Chunk 1
---
 prospectus supplement is to update the July 11, 2024 sales agreement prospectus to reflect the ATM Offering Size Reduction. Except as modified by this prospectus supplement, the terms of the ATM Offering remain unchanged, and the Offering Agreement remains in full force and effect.

As of the date of this prospectus supplement, the aggregate market value of our outstanding shares of common stock held by non-affiliates (the “public float”), was approximately $27,005,378, which was calculated based on our 13,920,298 outstanding shares of common stock held by non-affiliates at a price of $1,94 per share, the closing price of our common stock on the Nasdaq Capital Market on April 21, 2025. During the 12-calendar month period that ends on, and includes, the date of this prospectus supplement, we have offered $3,577,830 of securities pursuant to General Instruction I.B.6. of Form S-3. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our common stock in a public primary offering with a value exceeding more than one-third of the aggregate market value of our voting and non-voting common equity held by non-affiliates in any 12-month period as long as the aggregate market value of our outstanding voting and non-voting common equity held by non-affiliates is less than $75,000,000. In the event that we may sell additional amounts under the Offering Agreement, we will file another prospectus supplement prior to making such additional sales.

Our business and an investment in our common stock involve significant risks. These risks are described under the caption “Risk Factors” beginning on pages

#### S-6

#### and

#### 5
of the July 11, 2024 sales agreement prospectus and July 11, 2024 base prospectus, respectively, and in the documents incorporated by reference into the July 11, 2024 sales agreement prospectus and July 11, 2024 base prospectus, as well as the risks and uncertainties described in other documents we file with the Securities and Exchange Commission, or SEC.

Neither the SEC nor any state securities commission has approved of anyone’s investment in these securities or determined if this prospectus supplement, the July 11, 2024 sales agreement prospectus and July 11, 2024 base prospectus are truthful or complete. Any representation to the contrary is a criminal offense.

#### H